Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor

Stem Cells

Volumn 30, Issue 5, 2012, Pages 845-853

  Thirant, Cécile ^a   Galan Moya, Eva Maria ^b   Gustavo Dubois, Luiz ^a   Pinte, Sébastien ^c   Chafey, Philippe ^b   Broussard, Cédric ^b   Varlet, Pascale ^a,d   Devaux, Bertrand ^a,d   Soncin, Fabrice ^c   Gavard, Julie ^b   Junier, Marie Pierre ^a   Chneiweiss, Hervé ^a  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^b INSTITUT COCHIN   (France)

^c INSTITUT DE BIOLOGIE DE LILLE   (France)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Adult glioma; Cancer stem cells; Neoangiogenesis; Secreted factor; Tumor progression; Two dimensional differential gel electrophoresis

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; HEPATOMA DERIVED GROWTH FACTOR ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL PROTEOMIC ANALYSIS; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; NEURAL STEM CELL; PROTEIN EXPRESSION; PROTEOMICS; RADIOSENSITIVITY; TANDEM MASS SPECTROMETRY; TUMOR XENOGRAFT; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; FEMALE; GLIOBLASTOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEURAL STEM CELLS; PROTEOMICS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84860500514     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1062     Document Type: Article

References (85)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996. (Pubitemid 40349501)
2. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 2010;80:654-665.
3. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82. (Pubitemid 46054518)
4. Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-7848. (Pubitemid 44299144)
5. Folkins C, Shaked Y, Man S et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 2009;69:7243-7251.
6. Huang Z, Cheng L, Guryanova OA et al. Cancer stem cells in glioblastoma - molecular signaling and therapeutic targeting. Protein Cell 2011;1:638-655.
7. Galan-Moya EM, Le Guelte A, Lima Fernandes E et al. Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep 2011;12:470-476.
8. Lee J, Kotliarova S, Kotliarov Y et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403. (Pubitemid 43668737)
9. Kang MK, Kang SK. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 2007;16:837-847.
10. Liu G, Black KL, Yu JS. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 2006;5:233-247. (Pubitemid 44183378)
11. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
12. Lomonaco SL, Finniss S, Xiang C et al. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009;125:717-722.
13. Wang J, Wakeman TP, Lathia JD et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010;28:17-28.
14. Suh H, Deng W, Gage FH. Signaling in adult neurogenesis. Annu Rev Cell Dev Biol 2009;25:253-275.
15. Chirasani SR, Sternjak A, Wend P et al. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 2010;133(Pt 7):1961-1972.
16. Gangemi RM, Griffero F, Marubbi D et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009;27:40-48.
17. Hu Q, Zhang L, Wen J et al. The EGF receptor-sox2-EGF receptor feedback loop positively regulates the self-renewal of neural precursor cells. Stem Cells 2010;28:279-286.
18. Zbinden M, Duquet A, Lorente-Trigos A et al. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J 2010;29:2659-2674.
19. Clement V, Sanchez P, de Tribolet N et al. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007;17:165-172. (Pubitemid 46107823)
20. Bar EE, Chaudhry A, Lin A et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007;25:2524-2533. (Pubitemid 47582744)
21. Xu Q, Yuan X, Liu G et al. Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas. Stem Cells 2008;26:3018-3026.
22. Fareh M, Turchi L, Virolle V et al. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ 2012;19:232-244.
23. Hu TH, Huang CC, Liu LF et al. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 2003;98:1444-1456.
24. Everett AD, Narron JV, Stoops T et al. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 2004;286:L1194-L1201. (Pubitemid 38656655)
25. Iwasaki T, Nakagawa K, Nakamura H et al. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep 2005;13:1075-1080.
26. Yamamoto S, Tomita Y, Hoshida Y et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 2006;12:117-122. (Pubitemid 43166184)
27. Chang KC, Tai MH, Lin JW et al. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer 2007;121:1059-1065.
28. Lepourcelet M, Tou L, Cai L et al. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development 2005;132:415-427. (Pubitemid 40268290)
29. Ren H, Tang X, Lee JJ et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 2004;22:3230-3237. (Pubitemid 41103677)
30. Uyama H, Tomita Y, Nakamura H et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 2006;12(Pt 1):6043-6048. (Pubitemid 44703767)
31. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
32. Varlet P, Soni D, Miquel C et al. New variants of malignant glioneuronal tumors: A clinicopathological study of 40 cases. Neurosurgery 2004;55:1377-1391; discussion 1391-1372.
33. Thirant C, Bessette B, Varlet P et al. Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS One 2011;6:e16375.
34. Patru C, Romao L, Varlet P et al. CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer 2010;10:66.
35. Silvestre DC, Pineda JR, Hoffschir F et al. Alternative lengthening of telomeres in human glioma stem cells. Stem Cells 2011;29:440-451.
36. Weksler BB, Subileau EA, Perriere N et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005;19:1872-1874. (Pubitemid 41598779)
37. Thirant C, Varlet P, Lipecka J et al. Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1. Proteomics 2011;11:4139-4154.
38. Dufour C, Cadusseau J, Varlet P et al. Astrocytes reverted to a neural progenitor-like state with transforming growth factor alpha are sensitized to cancerous transformation. Stem Cells 2009;27:2373-2382.
39. Tan W, Palmby TR, Gavard J et al. An essential role for Rac1 in endothelial cell function and vascular development. FASEB J 2008;22:1829-1838. (Pubitemid 351811460)
40. Ayuso-Sacido A, Roy NS, Schwartz TH et al. Long-term expansion of adult human brain subventricular zone precursors. Neurosurgery 2008;62:223-229; discussion 229-231.
41. Liu A, Stadelmann C, Moscarello M et al. Expression of stathmin, a developmentally controlled cytoskeleton-regulating molecule, in demyelinating disorders. J Neurosci 2005;25:737-747.
42. Liu RZ, Mita R, Beaulieu M et al. Fatty acid binding proteins in brain development and disease. Int J Dev Biol 2010;54:1229-1239.
43. von Heijne G. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res 1986;14:4683-4690.
44. Nakamura H, Kambe H, Egawa T et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 1989;183:273-284. (Pubitemid 19219222)
45. Junier MP. What role (s) for TGFalpha in the central nervous system? Prog Neurobiol 2000;62:443-473.
46. Gao X, Tian HY, Liu L et al. Comparative proteomic analysis of proteins involved in cell aggregation during neural differentiation of P19 mouse embryonic carcinoma cells. J Proteome Res 2009;8:1765-1781.
47. Salim K, Kehoe L, Minkoff MS et al. Identification of differentiating neural progenitor cell markers using shotgun isobaric tagging mass spectrometry. Stem Cells Dev 2006;15:461-470. (Pubitemid 44100021)
48. Chaerkady R, Kerr CL, Marimuthu A et al. Temporal analysis of neural differentiation using quantitative proteomics. J Proteome Res 2009;8:1315-1326.
49. Wang D, Gao L. Proteomic analysis of neural differentiation of mouse embryonic stem cells. Proteomics 2005;5:4414-4426. (Pubitemid 41739919)
50. Nagano K, Taoka M, Yamauchi Y et al. Large-scale identification of proteins expressed in mouse embryonic stem cells. Proteomics 2005;5:1346-1361.
51. He H, Nilsson CL, Emmett MR et al. Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. J Proteome Res 2010;9:2098-2108.
52. Nilsson CL, Dillon R, Devakumar A et al. Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: An initial study in GSC11 glioblastoma stem cells. J Proteome Res 2010;9:430-443.
53. Mattila S, Tuominen H, Koivukangas J et al. The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas. Neuropathology 2009;29:156-165.
54. Roseman BJ, Bollen A, Hsu J et al. Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 1994;6:561-567.
55. Woo SH, An S, Lee HC et al. A truncated form of p23 down-regulates telomerase activity via disruption of Hsp90 function. J Biol Chem 2009;284:30871-30880.
56. Lee JH, Khadka P, Baek SH et al. CHIP promotes human telomerase reverse transcriptase degradation and negatively regulates telomerase activity. J Biol Chem 2010;285:42033-42045.
57. Di Michele M, Marcone S, Cicchillitti L et al. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: Towards the identification of putative biomarkers. J Proteomics 2010;73:879-898.
58. Reeves SA, Chavez-Kappel C, Davis R et al. Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res 1992;52:6871-6876. (Pubitemid 23006292)
59. Tatenhorst L, Puttmann S, Senner V et al. Genes associated with fast glioma cell migration in vitro and in vivo. Brain Pathol 2005;15:46-54. (Pubitemid 40224066)
60. Sauve AA. NAD+ and vitamin B3: From metabolism to therapies. J Pharmacol Exp Ther 2008;324:883-893.
61. Tomida M, Mikami I, Takeuchi S et al. Serum levels of nicotinamide N-methyltransferase in patients with lung cancer. J Cancer Res Clin Oncol 2009;135:1223-1229.
62. Emanuelli M, Santarelli A, Sartini D et al. Nicotinamide N-methyltransferase upregulation correlates with tumour differentiation in oral squamous cell carcinoma. Histol Histopathol 2010;25:15-20.
63. Kim J, Hong SJ, Lim EK et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009;28:20.
64. Wu Y, Siadaty MS, Berens ME et al. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 2008;27:6679-6689.
65. D'Andrea FP, Safwat A, Kassem M et al. Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance. Radiother Oncol 2011;99:373-378.
66. Ben-Porath I, Thomson MW, Carey VJ et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40:499-507. (Pubitemid 351601215)
67. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
68. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-173. (Pubitemid 43357943)
69. Li G, Chen Z, Hu YD et al. Autocrine factors sustain glioblastoma stem cell self-renewal. Oncol Rep 2009;21:419-424.
70. Surena AL, de Faria GP, Studler JM et al. DLG1/SAP97 modulates transforming growth factor alpha bioavailability. Biochim Biophys Acta 2009;1793:264-272.
71. Terasaki M, Sugita Y, Arakawa F et al. CXCL12/CXCR4 signaling in malignant brain tumors: A potential pharmacological therapeutic target. Brain Tumor Pathol 2011;28:89-97.
72. Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther 2009;8:1106-1112.
73. Okuda Y, Nakamura H, Yoshida K et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 2003;94:1034-1041. (Pubitemid 38035516)
74. Abouzied MM, Baader SL, Dietz F et al. Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem J 2004;378(Pt 1):169-176. (Pubitemid 38299554)
75. Yang J, Everett AD. Hepatoma-derived growth factor binds DNA through the N-terminal PWWP domain. BMC Mol Biol 2007;8:101.
76. Hsu SS, Chen CH, Liu GS et al. Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J Neurooncol 2012;107:101-109.
77. Zhao J, Yu H, Lin L et al. Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF). J Proteomics 2011;75:588-602.
78. Jain RK, di Tomaso E, Duda DG et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-622. (Pubitemid 47093931)
79. Venere M, Fine HA, Dirks PB et al. Cancer stem cells in gliomas: Identifying and understanding the apex cell in cancer's hierarchy. Glia 2011;59:1148-1154.
80. Ping YF, Yao XH, Jiang JY et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol 2011;224:344-354.
81. Jin X, Yin J, Kim SH et al. EGFR-AKT-SMAD signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res 2011;71:7125-7134.
82. Mellinghoff IK, Lassman AB, Wen PY. Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia 2011;59:1205-1212.
83. Reardon DA, Turner S, Peters KB et al. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw 2011;9:414-427.
84. Roitbak T, Li L, Cunningham LA. Neural stem/progenitor cells promote endothelial cell morphogenesis and protect endothelial cells against ischemia via HIF-1alpha-regulated VEGF signaling. J Cereb Blood Flow Metab 2008;28:1530-1542.
85. Thau-Zuchman O, Shohami E, Alexandrovich AG et al. Vascular endothelial growth factor increases neurogenesis after traumatic brain injury. J Cereb Blood Flow Metab 2010;30:1008-1016.